A UAB study sheds light on and suggests a target for treatment of a variant of Guillain-Barré syndrome.
August 04, 2016
July 28, 2016
The mechanism of widespread reorganization of DNA methylation may be a therapeutic target to prevent or reverse dyskinesia.
May 03, 2016
Results show that JAK/STAT pathway inhibitors may be a new class of therapeutic treatments for patients with Parkinson’s disease. Acting by reducing inflammation, they prevent neurodegeneration in animal models and may be an important new approach to slow progression of the disease.
March 15, 2016
Published in Service to Community
February 23, 2016
A key role for microRNA-155 in brain inflammation and neurodegeneration makes it both a potential therapeutic target and a biomarker for this progressive disorder.
February 19, 2016
January 11, 2016
UAB-led research shows how methylating an RNA binding protein leads to alternative RNA splicing. Mutant enzymes are often found in blood cancers.
March 03, 2015
The UAB studies are designed to test the safety and tolerability of CBD oil in patients with intractable seizures. CBD oil, a derivative of the cannabis plant, is delivered orally as an oily liquid.
Published in Focus on Patient Care
The Alzheimer’s plaques that accumulate around brain cells also congregate along the walls of blood vessels, according to UAB research, and that may contribute to cognitive issues.
November 03, 2015
Engineers, physicians, computer scientists and statisticians will collaborate to research and apply big data in the health care, industrial and smart cities fields.
A multisite study led by UAB has found the first biomarker for the onset of seizures in infants with tuberous sclerosis.
UAB's strengths in clinical care and research are powering an interdisciplinary expedition into largely uncharted territory: neuroinflammatory mechanisms in Parkinson's disease.
September 03, 2015
August 31, 2015
Oh honored with lifetime award from the American Association of Neuromuscular and Electrodiagnostic Medicine.
July 10, 2015
Haydeh Payami, Ph.D., a leading geneticist recruited to the UAB-Hudson Alpha Center for Genomic Medicine and UAB Personalized Medicine Institute, is exploring the protective power of coffee and nicotine — and the mysteries of the microbiome — in Parkinson’s disease.
The drug inhibits the activity of a kinase enzyme called LRRK2, and it showed no pathology in rat lungs, kidneys or livers.